title: Eosinophilic oesophagitis: a novel treatment using Montelukast.
abstract: BACKGROUND
  Eosinophilic oesophagitis is a rarely diagnosed condition involving eosinophil infiltration of the oesophageal mucosa and creating significant symptoms of dysphagia. Failure to diagnose this disorder relates to reluctance to biopsy an apparently normal oesophagus. This is essential for histological diagnosis. To date, treatment success has been achieved only with corticosteroids. We describe here the use of an eosinophil stabilising agent Montelukast for the symptomatic relief of these patients.
  
  
  METHODS
  Twelve patients have been identified with this condition in our unit since 1995, after thorough investigation of their dysphagia. We commenced eight of these patients on the leukotriene receptor antagonist Montelukast to symptomatically improve their swallowing while avoiding the use of long term corticosteroids.
  
  
  RESULTS
  Many of these patients had been previously misdiagnosed, and therefore inappropriately and unsuccessfully treated for an extensive period prior to referral to our unit. All patients were unresponsive to acid suppression therapy alone but showed improvement in their swallowing on Montelukast. Six of eight reported complete subjective improvement, five patients remaining completely asymptomatic on a maintenance regimen.
  
  
  CONCLUSIONS
  Eosinophilic oesophagitis is a disease that is often misdiagnosed due to lack of awareness and reluctance of clinicians to biopsy an apparently normal oesophagus in dysphagic patients, and therefore obtain a histological diagnosis. Investigation of these patients adds further evidence to this condition being a separate pathological state from gastro-oesophageal reflux and eosinophilic enteritis. Montelukast has been found to be of significant help in the symptomatic control of these patients while avoiding long term corticosteroids use.
authors.affiliation: Department of Upper Gastro-intestinal Surgery, Hope Hospital, Salford Royal Hospitals NHS Trust, Manchester, UK.
authors.forename: S E A
authors.initials: SE
authors.lastname: Attwood
authors.forename: C J
authors.initials: CJ
authors.lastname: Lewis
authors.forename: C S
authors.initials: CS
authors.lastname: Bronder
authors.forename: C D
authors.initials: CD
authors.lastname: Morris
authors.forename: G R
authors.initials: GR
authors.lastname: Armstrong
authors.forename: J
authors.initials: J
authors.lastname: Whittam
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D017668:Age of Onset; D001706:Biopsy; D003521:Cyclopropanes; D003680:Deglutition Disorders / Q000209:etiology / Q000473:pathology; D004802:Eosinophilia / Q000188:drug therapy* / Q000473:pathology; D004941:Esophagitis / Q000188:drug therapy* / Q000473:pathology; D004945:Esophagoscopy / Q000379:methods; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000627:therapeutic use*; D013440:Sulfides; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast